Kidney Cancer

DNA mutations linked to kidney cancer recurrence reveal way to optimize treatment
Researchers have linked tumor DNA mutations to kidney cancer recurrence, suggesting that treatment and follow-up can be optimized based on genetic factors.
February 23, 2023
Kidney Social
BrainChip, NaNose laud progress in breath sample COVID-19 test
The test incorporates NaNose Medical's sensor array to collect data and BrainChip's Akida artificial intelligence chip to perform the diagnosis, according to the two firms. NaNose's sensory array is based on technology developed at Technion Israel Institute of Technology in Haifa, and has similar sensitivity to minute quantities of volatile organic compounds (VOCs) as a dog's nose.
February 24, 2021
2021 02 25 23 48 3444 Covid Virus Dna Molecule 400
Veracyte to acquire Decipher Biosciences
Decipher has developed a portfolio of diagnostic tests for urologic cancers that use whole-transcriptome analysis and machine-learning algorithms. The company's genomic tests have been used by more than 3,200 urologists and radiation oncologists, according to Veracyte.
February 2, 2021
2021 02 03 17 37 9265 Computer Prostate Kidneys 400
Fast cancer screening brought to Taiwan
The iR-WPK technology utilizes a contrast agent to perform contrast-enhanced imaging of the glycan layer, a cell surface that is altered when cancer cells grow. The technique can also help diagnose and track the progression of chronic kidney disease.
October 25, 2020
2019 05 08 21 57 5547 Pathology Digital Workstation 400
AI-driven DNA methylation liquid biopsy shows promise in brain and kidney cancer
The method -- called cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) -- has been developed for blood and other kinds of liquid specimens. Testing screens for abnormal methylation, whereas liquid biopsy tests typically look for mutations, the researchers explained.
June 23, 2020
2020 06 23 22 33 5774 3 D Medical Imaging
MilliporeSigma to make Elypta liquid biopsy kits
Elypta's liquid biopsy kits analyze metabolites that are deregulated in several types of cancer, resulting in more accurate diagnoses, according to MilliporeSigma. The kits to be manufactured will use a biofluid sample to detect and analyze biological markers for cancer, enabling clinicians to diagnose patients and determine treatment options.
February 17, 2020
2019 09 06 17 09 1120 Cancer Cell Yellow 400
Most Popular
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
FDA reissues EUA for Janssen COVID-19 vaccine, includes warning about risks of myocarditis, pericarditis
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Netherlands researchers combine CRISPR, bioluminescence in proof-of-concept infectious disease test
Werfen completes $2B acquisition of Immucor, expands presence in specialized diagnostics
Page 1 of 1